I'll ask my colleagues to speak to the specific latter part of the question.
But I want to reassure the committee on the point that we have learned of some of these issues from elsewhere. I actually think that is a mark of the system working well. I'll just say that although we may hear of them from a foreign regulator, what we understand as a smaller country with fewer people on any given medication—some of which as my colleagues said, may have been introduced in other countries before they were actually on the market in Canada—is that we as regulators want to pool the signals. We want to pool the circumstances—